Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Adma Biologics (ADMA) over the last 10 years, with Q1 2025 value amounting to $1.7 million.

  • Adma Biologics' Gains from Investment Securities changed N/A to $1.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.7 million, marking a year-over-year increase of 2359225.71%. This contributed to the annual value of $17000.0 for FY2023, which is 9857.63% down from last year.
  • According to the latest figures from Q1 2025, Adma Biologics' Gains from Investment Securities is $1.7 million.
  • In the past 5 years, Adma Biologics' Gains from Investment Securities ranged from a high of $1.7 million in Q1 2025 and a low of $1000.0 during Q4 2023
  • Moreover, its 4-year median value for Gains from Investment Securities was $8683.0 (2021), whereas its average is $145454.8.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 9987.54% in 2021, then surged by 1184.43% in 2023.
  • Adma Biologics' Gains from Investment Securities (Quarter) stood at $8493.0 in 2021, then grew by 2.66% to $8719.0 in 2022, then plummeted by 88.53% to $1000.0 in 2023, then soared by 165745.8% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q1 2025, $1000.0 for Q4 2023, and $6000.0 during Q2 2023.